Logo image of FBLG

FIBROBIOLOGICS INC (FBLG) Stock Fundamental Analysis

NASDAQ:FBLG - Nasdaq - US31573L1052 - Common Stock - Currency: USD

1.65  +0.1 (+6.45%)

Premarket: 1.65 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to FBLG. FBLG was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of FBLG have multiple concerns. FBLG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FBLG has reported negative net income.
In the past year FBLG has reported a negative cash flow from operations.
FBLG Yearly Net Income VS EBIT VS OCF VS FCFFBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -5M -10M -15M

1.2 Ratios

FBLG has a worse Return On Assets (-169.83%) than 87.79% of its industry peers.
FBLG's Return On Equity of -649.58% is on the low side compared to the rest of the industry. FBLG is outperformed by 82.30% of its industry peers.
Industry RankSector Rank
ROA -169.83%
ROE -649.58%
ROIC N/A
ROA(3y)-201.8%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FBLG Yearly ROA, ROE, ROICFBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

FBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBLG Yearly Profit, Operating, Gross MarginsFBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, FBLG has more shares outstanding
FBLG has a better debt/assets ratio than last year.
FBLG Yearly Shares OutstandingFBLG Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
FBLG Yearly Total Debt VS Total AssetsFBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -3.61, we must say that FBLG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.61, FBLG is in line with its industry, outperforming 44.07% of the companies in the same industry.
FBLG has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.04, FBLG is not doing good in the industry: 61.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -3.61
ROIC/WACCN/A
WACCN/A
FBLG Yearly LT Debt VS Equity VS FCFFBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 -2M -4M -6M

2.3 Liquidity

A Current Ratio of 1.23 indicates that FBLG should not have too much problems paying its short term obligations.
FBLG has a Current ratio of 1.23. This is amonst the worse of the industry: FBLG underperforms 84.42% of its industry peers.
A Quick Ratio of 1.23 indicates that FBLG should not have too much problems paying its short term obligations.
FBLG has a worse Quick ratio (1.23) than 83.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
FBLG Yearly Current Assets VS Current LiabilitesFBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for FBLG have decreased strongly by -321.92% in the last year.
EPS 1Y (TTM)-321.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

FBLG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.63%
EPS Next 2Y20.2%
EPS Next 3Y8.32%
EPS Next 5Y4.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBLG Yearly Revenue VS EstimatesFBLG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
FBLG Yearly EPS VS EstimatesFBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBLG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBLG Price Earnings VS Forward Price EarningsFBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBLG Per share dataFBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.2%
EPS Next 3Y8.32%

More info and screens

0

5. Dividend

5.1 Amount

FBLG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIBROBIOLOGICS INC

NASDAQ:FBLG (2/5/2025, 8:00:01 PM)

Premarket: 1.65 0 (0%)

1.65

+0.1 (+6.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners9.63%
Inst Owner Change-0.73%
Ins Owners17.59%
Ins Owner Change-2.18%
Market Cap57.90M
Analysts82.22
Price Target13.01 (688.48%)
Short Float %9.29%
Short Ratio15.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.45%
Min EPS beat(2)78.21%
Max EPS beat(2)88.69%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)17.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 21.15
P/tB 21.15
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -169.83%
ROE -649.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-201.8%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -3.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-321.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.69%
EPS Next Y48.63%
EPS Next 2Y20.2%
EPS Next 3Y8.32%
EPS Next 5Y4.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-98.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.43%
OCF growth 3YN/A
OCF growth 5YN/A